Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Andrew G Gianoukakis1 Division of Endocrinology and Metabolism, Harbor-UCLA Medical Center, The University of California, Los Angeles, USA

Natalia M Flores2 Health Outcomes Research, Kantar Health, Foster City, CA, USACorrespondence[email protected]

Corey L Pelletier3 Global Value and Access, Eisai, Inc., Woodcliff Lakes, NJ, USA

Anna Forsythe3 Global Value and Access, Eisai, Inc., Woodcliff Lakes, NJ, USA

Gregory R Wolfe2 Health Outcomes Research, Kantar Health, Foster City, CA, USA

Matthew H Taylor4 Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA

Pages 67-76 | Published online: 30 May 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

American Cancer Society [webpage on the Internet]Thyroid Cancer2013 Available from: http://www.cancer.org/Cancer/ThyroidCancer/DetailedGuide/thyroid-cancer-key-statisticsAccessed May 21, 2013
Google Scholar
International Agency for Research on Cancer [webpage on the Internet]Thyroid Cancer: Estimated Incidence, Mortality and Prevalence for Both Sexes, 20122012 Available from: http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=35Accessed November 23, 2014
Google Scholar
AndersonRTLinnehanJETongbramVKeatingKWirthLJClinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature reviewThyroid201323439240723294230
PubMed Web of Science ®Google Scholar
PellegritiGFrascaFRegalbutoCSquatritoSVigneriRWorldwide increasing incidence of thyroid cancer: update on epidemiology and risk factorsJ Cancer Epidemiol2013201396521223737785
PubMedGoogle Scholar
American Cancer SocietyCancer Facts and Figures 2014AtlantaAmerican Cancer Society, Inc2014
Google Scholar
BurnsWRZeigerMADifferentiated thyroid cancerSemin Oncol201037655756621167375
PubMed Web of Science ®Google Scholar
JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
PubMed Web of Science ®Google Scholar
McFarlandDCMisiukiewiczKJSorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancerOnco Targets Ther201471291129925053887
PubMed Web of Science ®Google Scholar
BroseMSNuttingCMJarzabBSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
PubMed Web of Science ®Google Scholar
SchlumbergerMTaharaMWirthLJLenvatinib versus placebo in radioiodine-refractory thyroid cancerN Engl J Med2015372762163025671254
PubMed Web of Science ®Google Scholar
SacksWBraunsteinGDEvolving approaches in managing radioactive iodine-refractory differentiated thyroid cancerEndocr Pract201420326327524126232
PubMed Web of Science ®Google Scholar
WordenFTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerTher Adv Med Oncol20146626727925364392
PubMed Web of Science ®Google Scholar
DaduRCabanillasMEOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsMinerva Endocrinol201237433535623235190
PubMed Web of Science ®Google Scholar
SarlisNJGourgiotisLUnresolved issues, dilemmas and points of interest in thyroid cancer: a current perspectiveHormones (Athens)20043314917016982589
PubMedGoogle Scholar
BroseMSSmitJCapdevilaJRegional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinomaExpert Rev Anticancer Ther20121291137114723098114
PubMed Web of Science ®Google Scholar
DingleIFMishoeAENguyenSAOvertonLJGillespieMBSalivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancerOtolaryngol Head Neck Surg2013148574675223462656
PubMed Web of Science ®Google Scholar
GallopKKerrCSimmonsSMcIverBCohenEEA qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phasesQual Life Res201524232533825106505
PubMed Web of Science ®Google Scholar
KerrCFordhamBde FreitasHMHealth state utility valuation in radio-iodine refractory differentiated thyroid cancer (RR-DTC)ISPOR 17th Annual European CongressAmsterdam2014
Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date